Cell News and Research

RSS

New discovery provides insights into how seasonal influenza viruses infect people

Scientists investigating how influenza viruses replicate within cells "accidentally" discovered that different flu viruses use distinct strategies to infiltrate cells in the first place.

2 Jun 2026

Stem cell transplantation is the most cost-effective sickle cell treatment

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared with gene therapy and standard of care treatment, according to new research published in Blood.

2 Jun 2026

Building quality into drug development for safer, faster medicines

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 2 Jun 2026

Tissue rigidity actively regulates cell polarity and embryonic development

Embryonic development is one of the most dynamic biological processes in nature. Cells and tissues organise and reorganise themselves following incredibly precise patterns, while remaining flexible and robust.

2 Jun 2026

Magnetic microrobots deliver stem cells to heal spinal cord injuries

A research team from ETH Zurich and the University of Zurich (UZH) has developed a novel approach to treating spinal cord injuries: controllable microrobots deliver stem cells directly to the site of an injury, where they promote nerve cell regeneration.

2 Jun 2026

New ultrasound pacemaker design promises minimal recovery time for cardiac patients

MIT engineers have developed a noninvasive pacemaker that stimulates the heart using ultrasound. The design could one day provide a surgery-free alternative to traditional cardiac implants.

2 Jun 2026

Cellular reprogramming helps outsmart progressive Alzheimers disease

A team led by researcher José Vicente Sánchez Mut at the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and the Miguel Hernández University of Elche (UMH), together with researcher Johannes Gräff at the École Polytechnique Fédérale de Lausanne (EPFL), has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their protective function against Alzheimer's disease.

2 Jun 2026

New magnetic particle imaging ensures precision cell therapy injection tracking

Scientists at Johns Hopkins Medicine say they used a form of magnetic imaging to track cell therapy injections commonly used to treat certain autoimmune diseases and cancers.

2 Jun 2026

New blood test tracks real time gene expression inside living brain tissue

Cell function is determined by how DNA is expressed into proteins. That process includes two main steps - transcription, when messenger RNA (mRNA) makes copies of active genes, and translation, when mRNA guides protein assembly.

2 Jun 2026

New mRNA treatment improves recovery following heart attacks

A heart attack is far from being an isolated, acute event. The consequences of an attack can cause serious and lasting damage, including heart failure.

1 Jun 2026

E-cigarette flavors and device type drive the biological effects of vaping

People who vape regularly show altered activity in 3,124 genes across the genome compared with people who do not smoke or vape.

1 Jun 2026

Pediatric experts reveal the 10 research areas set to shape child health

Pediatric research leaders identified 10 high-promise areas likely to shape child health over the next 5 to 10 years, including genomics, mental health, vaccines, artificial intelligence, perinatal medicine, precision therapeutics, health equity, nutrition, environmental health, and cancer treatment. The paper argues that these opportunities will only translate into better outcomes if pediatric research receives sustained funding, public trust, workforce support, advocacy, and equitable implementation.

1 Jun 2026

New PET tracer offers a powerful tool for kidney cancer staging

A new PET tracer targeting carbonic anhydrase IX (CAIX) has demonstrated exceptional sensitivity and high tumor-to-background contrast in detecting clear cell renal cell carcinoma (ccRCC), according to early clinical research.

1 Jun 2026

Jumping genes help strengthen the mammalian Y chromosome

The humble Y chromosome may be the smallest chromosome in the mammalian genome (and getting even smaller), but it is mighty: genes on the Y chromosome are critical for fertility in males.

1 Jun 2026

Mature intestinal cells regain stem cell behavior to trigger tumor growth

In a groundbreaking study, Stevens researchers show how colorectal cancers can evolve from mature intestinal cells that revert to stem cells.

1 Jun 2026

New atlas provides unprecedented overview of dendritic cell diversity across cancers

Researchers from VIB, VUB, and an international network of collaborators have created the most comprehensive single-cell atlas to date of tumor-associated dendritic cells.

1 Jun 2026

Vaccine and drug combination cuts melanoma recurrence by half

The combination of a vaccine and a drug, which both harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence by 49 percent, a new study shows.

1 Jun 2026

Understanding mitochondrial biology in alcohol-associated liver disease and cancer

For decades, giant mitochondria-known as megamitochondria-have been recognized in liver biopsies from patients with alcohol-associated liver disease (ALD).

1 Jun 2026

New SMArT platform improves safety of CRISPR gene editing

A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a new strategy to significantly improve the precision and safety of CRISPR-Cas9 gene editing in human blood stem cells, potentially overcoming one of the major barriers limiting broader clinical application of genome editing therapies.

1 Jun 2026

Laverock Therapeutics awarded in excess of £2.2 M through two innovation grants to support AI-powered platform development and to expand therapeutic programs outside of oncology

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totaling in excess of £2.2 M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.

From Laverock Therapeutics 1 Jun 2026